Stocks Health care URGN
NASDAQ · Health careUroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. brought in $188.7M of revenue over the twelve months to June 30, 2026, up 100.3% from a year earlier. It posted a net loss of $97.6M. In fiscal 2025 capital spending exceeded operating cash flow by $162.7M. At June 30, 2026 it held $79.1M in cash against $200M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 5, 2026.
What UroGen Pharma Ltd. does
UroGen Pharma Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker URGN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $109.8M | -$153.5M | -$3.19 | -$162.7M |
| 2024 | $90.4M | -$126.9M | -$2.96 | -$97.1M |
| 2023 | $82.7M | -$102.2M | -$3.55 | -$76.6M |
| 2022 | $64.4M | -$109.8M | -$4.81 | -$87.8M |
| 2021 | $48M | -$110.8M | -$4.96 | -$85.6M |
| 2020 | $11.8M | -$128.5M | -$5.90 | -$107.1M |
Where URGN ranks in Health care
Latest SEC filings
What UroGen Pharma Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 20, 2026Other event 8-K
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026
- August 5, 2026
- June 23, 2026
- June 2, 2026Other event 8-K
- May 27, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026
Insider trades
What the people running UroGen Pharma Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 8, 2026 | Smith Jason DrewGeneral Counsel | Sold | 1,519 | $64.6K |
| September 8, 2026 | Schoenberg MarkChief Medical Officer | Sold | 871 | $37.4K |
| September 7, 2026 | Smith Jason DrewGeneral Counsel | Exercised options | 3,334 | - |
| September 7, 2026 | Schoenberg MarkChief Medical Officer | Exercised options | 1,667 | - |
| August 26, 2026 | Robinson James A. Jr.Director | Exercised options | 2,000 | - |
| August 20, 2026 | Schoenberg MarkChief Medical Officer | Sold | 60,677 | $2.9M |
Questions about URGN
What does UroGen Pharma Ltd. do?
UroGen Pharma Ltd. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker URGN.
Is UroGen Pharma Ltd. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $97.6M on revenue of $188.7M.
How much revenue does UroGen Pharma Ltd. make?
Over the twelve months to June 30, 2026 UroGen Pharma Ltd. reported revenue of $188.7M. That is 100.3% more than a year earlier.
When did UroGen Pharma Ltd. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 5, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 9, 2026.
Similar companies
Compare URGN with
Follow URGN
Get an email when UroGen Pharma Ltd. files with the SEC: results, executive changes, material agreements and annual reports.
Follow URGN: get an email when it filesWhere the numbers come from
Financial figures are the values UroGen Pharma Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.